<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001063.v1.p1" parentStudy="phs001063.v1.p1" createDate="2016-01-29" modDate="2016-05-10">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Jean J. Zhao, PhD</td><td>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA</td></tr>
		<tr><td>Co-Principal Investigators</td><td>Keith L. Ligon, MD, PhD</td><td>Dana-Farber Cancer Institute, Boston Children&#39;s Hospital, Brigham and Women&#39;s Hospital, Harvard Medical School, Boston, MA, USA</td></tr>
		<tr><td>Co-Principal Investigators</td><td>Nancy U. Lin, MD</td><td>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA</td></tr>
		<tr><td>Co-Principal Investigators</td><td>Eric P. Winer, MD</td><td>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA</td></tr>
		<tr><td>Co-Investigators</td><td>Jing Ni, PhD</td><td>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Genomic Characterization of PDX Models for Breast Cancer Brain Metastases</StudyNameEntrez>
	<StudyNameReportPage>Genomic Characterization of Patient-Derived Xenograft Models to Improve Targeted Therapy for HER2+ Breast Cancer Brain Metastases Treatments</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>We have developed orthotopic patient-derived xenograft models of HER2 positive breast cancer metastasized into the brain of patients to test novel therapeutic strategies. In this study, we identified a novel combinatorial therapeutic strategy that has resulted in a durable remission and markedly increased overall survival in majority of patient-derived xenograft (PDX) models tested. We performed whole exome sequencing analysis of these PDX tumors and their matched blood and patient samples to investigate drug sensitive and resistance mechanisms. Our sequencing data revealed an interesting association of genotyping and phenotyping with tumors responses to drug treatment.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Her2+ breast cancers that metastasized to the brain</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Ni J, Ramkissoon S, Xie S, Goel S, et al." title="Combination inhibition of PI3K and mTORC1 yields durable remissions in orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases" journal="Nature Medicine (Accepted)"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Breast Neoplasms"/>
		<Disease vocab_source="MESH" vocab_term="Neoplasm Metastasis"/>
		<Disease vocab_source="MESH" vocab_term="Brain Neoplasms"/>
		<Disease vocab_source="MESH" vocab_term="Neoplasm Transplantation"/>
		<Disease vocab_source="MESH" vocab_term="Molecular Targeted Therapy"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Jean J. Zhao, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Keith L. Ligon, MD, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, Boston Children&#39;s Hospital, Brigham and Women&#39;s Hospital, Harvard Medical School, Boston, MA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Nancy U. Lin, MD</AttName>
			<Institution>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigators">
			<AttName>Eric P. Winer, MD</AttName>
			<Institution>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Jing Ni, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Shakti H. Ramkissoon, MD, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, Boston Children&#39;s Hospital, Brigham and Women&#39;s Hospital, Harvard Medical School, Boston, MA, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Shaozhen Xie, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Daniel G. Stover, MD, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Shom Goel, MD, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Lori A. Ramkissoon, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA</Institution>
		</Header>
		<Header title="Other Investigator">
			<AttName>Thomas M. Roberts</AttName>
			<Institution>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU-IRB-PUB" longName="General Research Use (IRB, PUB)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs001063.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>yes</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001063.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001063.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use (IRB, PUB)</ConsentName>
        <ConsentAbbrev>GRU-IRB-PUB</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.
Requestor must provide documentation of local IRB approval.
Requestor agrees to make results of studies using the data available to the larger scientific community.</UseLimitation>
        <IrbRequired>Yes</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
